Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

LXRX Sales of Investments

Cash received from selling or redeeming investments.

Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX

Sales of Investments · Q1 FY2026 · quarter ended Mar 2026

Sales of investments declines year over year

Q1 FY2026 sales of investments of $35.7M fell 66.2% year over year, behind the -47.3% change in trailing-twelve-month sales of investments. Sequentially, it rose 32.2% from the prior quarter. Over 3 fiscal years it compounded at +57.9% a year.

Context

  • Sales of investments amounted to 507.7% of revenue in FY2025, down 503.8 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -66.2% toward the trailing-twelve-month pace of -47.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$35.7M+32.2% QoQ
Last fiscal yearDec 2025
$252.86M-19.6% YoY
LTMMar 2026
$183M-47.3% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-66.2%——
1 year-19.6%——
3-year CAGR+57.9%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
252.86M USD
Year-over-year change
-19.6%
4-year CAGR
+61.0%

Sales of Investments vs competitors

How LXRX compares with its peers on the latest reported figures

  • LXRX's LTM Mar 2026 sales of investments of $183M is the 6th largest of the 11 companies compared; the peer median is $179.22M.
  • Its year-over-year change of -47.3% is the 10th highest of 11, against a peer median of +4.1%.
  • Sales of investments amounts to 262.8% of revenue for LXRX, versus a peer median of 93.4%.
LXRX Competitors Peer median
Sales of Investments for LXRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$1.82B +4.9%+19.7%189.3%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$1.34B +87.1%+18.2%132.6%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$368.93M +61.7%+29.8%39.2%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$225M -27.4%+24.5%—
MNKDMannKind CorporationLTM Mar 2026$195.82M -11.7%—54.3%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$183M -47.3%+57.9%262.8%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.63M -44.8%+51.8%—
TRVITrevi Therapeutics, Inc.LTM Sep 2026$130.21M +76.6%+58.0%—
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$65.97M +55.1%-15.5%22.0%
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$60.46M +3.3%-0.1%—
OVIDOvid Therapeutics Inc.LTM Mar 2026$42M -61.1%-22.4%589.7%
Peer median (excluding LXRX) $179.22M+4.1%+19.7%93.4%

Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Depreciation & Amortization292K427K554K534K621K
Deferred Income Tax49K0000
Stock-Based Compensation10.58M11.52M14.34M13.5M12.52M
Change in Working Capital(10.23M)402K2.66M14.24M(26.89M)
Accounts Receivables381K(14K)(982K)(2.46M)1.09M
Inventory00(381K)150K(50K)
Accounts Payables(14.16M)76K6.45M14.8M(30.22M)
Other Working Capital3.55M340K(2.43M)1.75M2.29M
Other Non-Cash Items54K744K(2.33M)(6.65M)(3.75M)
Operating Cash Flow(87.02M)(88.85M)(161.9M)(178.78M)(67.85M)
Capital Expenditures(1.22M)(1.33M)(470K)(1.03M)0
Acquisitions (Net)(3.33M)69.75M000
Purchases of Investments(34.26M)(133.95M)(223.34M)(338.05M)(143.55M)
Sales of Investments37.59M64.2M173.87M314.4M252.86M
Other Investing Activities3.33M(69.75M)09.31M3.71M
Investing Cash Flow2.11M(71.08M)(49.94M)(15.38M)113.02M
Debt Repayment(11.7M)48.87M49.96M0(48M)
Common Stock Issued37.08M94.21M138.82M64K73K
Common Stock Repurchased(2.68M)(864K)(824K)(1.73M)0
Dividends Paid00000
Other Financing Activities094.21M0(1.24M)(572K)
Financing Cash Flow22.71M142.21M187.96M238.35M(48.5M)
Effect of Forex Changes00000
Net Change in Cash(62.2M)(17.72M)(23.88M)44.19M(3.33M)
Free Cash Flow(88.24M)(90.18M)(162.37M)(179.81M)(67.85M)

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Intrinsic Alpha fair value

Locked

Current Price

$1.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.